Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter

  • 280 Accesses

  • 51 Citations


Cytidine deaminase (CDA) hydrolytically deaminates and irreversibly deactivates the chemotherapeutic agent cytosine arabinoside (Ara-C), a deoxycytidine analog used for treatment of acute leukemias and lymphomas. To determine if single nucleotide polymorphisms (SNPs) in the promoter region of CDA affected gene expression, we sequenced approximately 1.6 Kb upstream of the CDA translation initiation site and containing the proximal promoter of CDA. We identified 6 SNPs; -92A>G, -205C>G, -451C>T, -897C>A, -1075A>G and -1181G>A. Based on predicted changes in transcription factor binding sites, three SNPs (-92A>G, -451C>T and -897C>A) were chosen for further investigation. The five haplotypes segregating in the population were cloned into a luciferase expression plasmid, transfected into Cos-1 cells and reporter activity measured at 24 and 48 h. Four haplotypes showed an average expression which was 2.5-fold higher at 24 h (P<0.0001) and 3.3-fold higher at 48 h (P<0.0001) than the lowest expressing haplotype. When reanalyzed as single SNP genotypes, the differences in expression were significant, except for -897 C/A, at 24 h, but the magnitude of difference was reduced, suggesting that no single SNP completely accounts for the expression differences observed at the haplotype level. As predicted from the in vitro analysis, individuals homozygous for common haplotype (ACC/ACC) showed higher levels of CDA enzymatic activity as individuals heterozygous for the wild type and low expressing haplotype (ACC/ATC). As CDA promoter region haplotypes may influence Ara-C chemosensitivity, shown here in in vitro and in vivo studies, the clinical relevance of these findings should be examined.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3


  1. American Cancer Society (2004) Cancer facts and figures. http://www.cancer.org

  2. Arceci RJ (2000) Can multidrug resistance mechanisms be modified? Br J Haematol 110:285–291

  3. Betts L, Xiang S, Short SA, Wolfenden R, Carter CW Jr (1994) Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex. J Mol Biol 235:635–656

  4. Cacciamani T, Vita A, Cristalli G, Vincinzetti S, Natalini P, Ruggieri S, Magni G (1991) Purification of human cytidine deaminase: molecular and enzymatic characterization and inhibition by synthetic pyrimidine analogs. Arch Biochem Biophys 290:285–292

  5. Chabner B (1990) Cytidine analogs. In: Chabner BA, Collins JM (eds) Cancer chemotherapy: principals and practice. JB Lippincott, New York, pp 152–179

  6. Colly LP, Peters WG, Richel D, Arentsen-Honders MW, Starrenburg CW, Willemze R (1987) Deoxycytidine kinase and deoxycytidine deaminase values correspond closely to clinical response to cytosine arabinoside remission induction therapy in patients with acute myelogenous leukemia. Semin Oncol 14(Suppl 1):257–261

  7. DeAngelis LM, Kreis W, Chan K, Dantis E, Akerman S (1992) Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside. Cancer Chemother Pharmacol 29:173–177

  8. Demontis S, Terao M, Brivio M, Zanotta S, Bruschi M, Garattini E (1998) Isolation and characterization of the gene coding for human cytidine deaminase. Biochem Biophys Acta 1443:323–333

  9. Fukunaga AK, Marsh S, Murry DJ, Hurley TD, McLeod HL (2004) Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J 4:307–314

  10. Galmarini CM, Mackey JR, Dumontet C (2001) Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15:875–890

  11. Ge Y, Jensen TL, Stout ML, Flatley RM, Grohar PJ, Ravindranath V et al. (2004) The role of cytodine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down Syndrome myoblasts and leukemia cell lines. Cancer Res 64:728–735

  12. Gran C, Boyum A, Johansen RF, Lovhaug D, Seeberg EC (1998) Growth inhibition of granulocyte-macrophage colony-forming cells by human cytidine deaminase requires the catalytic function of the protein. Blood 91:4127–4135

  13. Ho DH, Frei E (1971) Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine. Clin Pharmacol Ther 12:944–954

  14. Jahns-Streubel G, Reuter C, Auf der Landwehr U, Unterhalt M, Schleyer E, Warmann B, Buckner T, Hiddemann W (1997) Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia. Blood 90:1968–1976

  15. Kirch HC, Schroder J, Hoppe H, Esche H, Seeber S, Schutte J (1998) Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol 26:421–425

  16. Kuhn K, Bertling WM, Emmrich F (1993) Cloning of a functional cDNA for human cytidine deaminase (CDD) and its use as a marker of monocyte/macrophage differentiation. Biochem Biophys Res Commun 190:1–7

  17. Laliberte J, Momparler RL (1994) Human cytidine deaminase: purification of enzyme, cloning, and expression of its complementary DNA. Cancer Res 54:5401–5407

  18. Momparler RL, Eliopoulos N, Bovenzi V, Letourneau S, Greenbaum M, Cournoyer D (1996) Resistance to cytosine arabinoside by retrovirally mediated gene transfer of human cytidine deaminase into murine fibroblast and hematopoietic cells. Cancer Gene Ther 3:331–338

  19. Muller WE, Zahn RK (1979) Metabolism of 1-beta-D-arabinofuranosyluracil in mouse L5178Y cells. Cancer Res 39:1102–1107

  20. Neff T, Blau CA (1996) Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine. Exp Hematol 24:1340–1346

  21. Onetto N, Momparler RL, Momparler LF, Gyger M (1987) In vitro biochemical tests to evaluate the response to therapy of acute leukemia with cytosine arabinoside or 5-AZA-2′-deoxycytidine. Semin Oncol 14(Suppl 1):231–237

  22. Osborne WRA, Miller AD (1988) Design of vectors for efficient expression of human purine nucleoside phosphorylase in skin fibroblasts from enzyme-deficient humans. Proc Natl Acad Sci USA 85:6851–6855

  23. Osborne WRA, Hock RA, Kaleko M, Miller AD (1990) Long-term expression of human adenosine deaminase in mice after transplantation of bone marrow infected with amphotropic retroviral vectors. Hum Gene Ther 1:31–41

  24. Schroder JK, Kirch C, Flasshove M, Kalvert H, Seidelmann M, Hilger R, Seeber S, Schutte J (1996) Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. Leukemia 10:1919–1924

  25. Schroder JK, Kirch C, Seeber S, Schutte J (1998) Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br J Haematol 103:1096–1103

  26. Smyth JF, Robins AB, Leese CL (1976) The metabolism of cytosine arabinoside as a predictive test for clinical response to the drug in acute myeloid leukaemia. Eur J Cancer 12:567–573

  27. Steuart CD, Burke PJ (1971) Cytidine deaminase and the development of resistance to arabinosyl cytosine. Nat New Biol 233:109–110

  28. Tattersall MH, Ganeshaguru K, Hoffbrand AV (1974) Mechanisms of resistance of human acute leukaemia cells to cytosine arabinoside. Br J Haematol 27:39–46

  29. Vincenzetti S, Cambi A, Neuhard J, Garattini E, Vita A (1996) Recombinant human cytidine deaminase: expression, purification, and characterization. Protein Expr Purif 8:247–253

  30. Watanabe S, Uchida T (1996) Expression of cytidine deaminase in human solid tumors and its regulation by 1 alpha,25-dihydroxyvitamin D3. Biochim Biophys Acta 1312:99–104

  31. Yonemori K, Ueno H, Okusaka T, Yamamoto N, Ikeda M et al (2005) Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 11:2620–2624

  32. Yue L, Saikawa Y, Ota K, Tanaka M, Uehara T, Maeba H (2003) A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 13:29–38

  33. Yusa K, Oh-hara T, Tsuruo T (1995) Induction of resistance to 1-beta-D-arabinofuranosylcytosine in human H9 cell line by simian immunodeficiency virus. Biochem Biophys Res Commun 206:486–491

Download references


This work was supported in part by a generous gift from Dr. and Mrs. William A. Sollecito.

Author information

Correspondence to R. E. Ferrell.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Fitzgerald, S.M., Goyal, R.K., Osborne, W.R.A. et al. Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum Genet 119, 276 (2006). https://doi.org/10.1007/s00439-006-0142-0

Download citation


  • Restriction Fragment Length Polymorphism Analysis
  • Cytosine Arabinoside
  • Cytidine Deaminase
  • Purine Nucleoside Phosphorylase
  • Haplotype Level